Fiorella Schischlik
YOU?
Author Swipe
View article: DeepTarget predicts anti-cancer mechanisms of action of small molecules by integrating drug and genetic screens
DeepTarget predicts anti-cancer mechanisms of action of small molecules by integrating drug and genetic screens Open
Identifying the mechanisms of action (MOA) driving a drug's anti-cancer efficacy is critical for its clinical success, guiding the search for its best biomarkers, indications and combinations. Yet, systematically identifying MOAs remains c…
View article: Supplementary Table 2 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Table 2 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Table 2
View article: Supplementary Figure 1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 1
View article: Supplementary Figure 4 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 4 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 4
View article: Supplementary Figure 5 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 5 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 5
View article: Supplementary Table 1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Table 1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Table 1
View article: Supplementary Figure 2 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 2 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 2
View article: Supplementary Figure 9 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 9 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 9
View article: Supplementary Figure 13 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 13 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 13
View article: Supplementary Figure 10 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 10 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 10
View article: Supplementary Figure 3 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 3 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 3
View article: Supplementary Figure 6 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 6 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 6
View article: Supplementary Figure 8 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 8 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 8
View article: Supplementary Material SM2 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Material SM2 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Comprehensive lists of all signatures predicting patient ICB response.
View article: Supplementary Figure 12 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 12 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 12
View article: Supplementary Figure 11 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 11 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 11
View article: Supplementary Material SM1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Material SM1 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
A list of predictable genes in different immune cell types.
View article: Supplementary Figure 7 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood
Supplementary Figure 7 from Inferring Characteristics of the Tumor Immune Microenvironment of Patients with HNSCC from Single-Cell Transcriptomics of Peripheral Blood Open
Supplementary Figure 7
View article: Supplementary Figure 1 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 1 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 1: Cellular sensitivity to BI-2493 integrated with CRISPR and RNAi gene dependency data. (Top) CRISPR: Drug-target associations show selectivity of BI-2493 for KRAS but not for HRAS and NRAS. Panel left, mid and right …
View article: Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
BI-2493 suppresses tumor growth in xenograft models of KRAS WT–amplified cancers. A, Antitumor activity of BI-2493 in the DMS 53 small cell lung cancer (SCLC) CDX model (left) and the MKN1 gastric cancer (GC) CDX model (right). BI-2493 was…
View article: Data from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Data from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
KRASG12C selective inhibitors, such as sotorasib and adagrasib, have raised hopes of targeting other KRAS-mutant alleles in patients with cancer. We report that KRAS wild-type (WT)–amplified tumor models are sensitive to treatment with the…
View article: Figure 2 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Figure 2 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
KRAS WT–amplified tumors are enriched in gastroesophageal cancers. A, TCGA cohort was queried for KRAS WT–amplified patients. Frequency of KRAS WT–amplified patients is shown, stratified by different thresholds of KRAS relative CNs. Only t…
View article: Supplementary Figure 9 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 9 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 9: BI-2493 and BI-2865 treatment induces cell cycle arrest and apoptosis in KRAS wild-type amplified cancer cell lines. (A) Upper panel: Representative flow blots of cell cycle states determined by EdU incorporation in…
View article: Supplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 3. Relationship between KRAS wild-type amplification and KRAS oncogenic activity in cell lines. RAS activation signatures (1,3) MSigDB, KrasLA, KRASG13D134, HRAS, MPAS, ras84 and RAS addiction in KRAS wild-type amplifi…
View article: Supplementary Figure 10 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 10 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 10. BI-2493 treatment in animal models is tolerated. % bodyweight change in xenograft models treated with control vehicle or BI-2493. Data represent the mean % bodyweight change +/- SEM of mice grafted with: (A) DMS 53…
View article: Supplementary Figure 8 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 8 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 8: KRAS wild-type amplified cancer cell lines are sensitive to pan-KRAS inhibitors BI-2493 and BI-2865. (A) Inhibition of pERK by BI-2493, BI-2865 and trametinib at the indicated timepoints and for the indicated cell l…
View article: Supplementary Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 4. Correlation between signatures for KRAS activation and sensitivity to BI-2493 across the KRAS wild-type amplified cell panel. RAS activation signatures were obtained from East et al. (1). Correlation coefficient bet…
View article: Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
KRAS WT–amplified cancer cell lines are sensitive to pan-KRAS inhibitors BI-2493 and BI-2865. A, Cell lines tested for sensitivity to pan-KRAS inhibitors were ranked according to KRAS WT relative CN. Tumor of origin and KRAS WT gene expres…
View article: Supplementary Tables 1-5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Tables 1-5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Table 1: PRISM data integrated with omics data from depmap Supplementary Table 2:Top 20 sensitive cell lines (PRISM) Supplementary Table 3:Frequency of KRAS WT AMP in AACR Genie v 15.1 (MSK cohort) Supplementary Table 4: Mutu…
View article: Supplementary Figure 7 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 7 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification Open
Supplementary Figure 7. Gastroesophageal cancers are enriched in KRAS wild-typeWT amplified tumors. Gastroesophageal cancers (n=3464) were selected from the AACR Genie MSK and DFCI cohort (version v16.0-public). Only patients with any alte…